PBYI
Price
$2.97
Change
-$0.05 (-1.66%)
Updated
Jan 17 closing price
Capitalization
145.79M
40 days until earnings call
VNDA
Price
$4.36
Change
-$0.08 (-1.80%)
Updated
Jan 17 closing price
Capitalization
254.22M
18 days until earnings call
Ad is loading...

PBYI vs VNDA

Header iconPBYI vs VNDA Comparison
Open Charts PBYI vs VNDABanner chart's image
Puma Biotechnology
Price$2.97
Change-$0.05 (-1.66%)
Volume$545.06K
Capitalization145.79M
Vanda Pharmaceuticals
Price$4.36
Change-$0.08 (-1.80%)
Volume$330.16K
Capitalization254.22M
PBYI vs VNDA Comparison Chart
Loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VNDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PBYI vs. VNDA commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBYI is a Hold and VNDA is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (PBYI: $2.97 vs. VNDA: $4.36)
Brand notoriety: PBYI and VNDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PBYI: 84% vs. VNDA: 55%
Market capitalization -- PBYI: $145.79M vs. VNDA: $254.22M
PBYI [@Biotechnology] is valued at $145.79M. VNDA’s [@Biotechnology] market capitalization is $254.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBYI’s FA Score shows that 1 FA rating(s) are green whileVNDA’s FA Score has 1 green FA rating(s).

  • PBYI’s FA Score: 1 green, 4 red.
  • VNDA’s FA Score: 1 green, 4 red.
According to our system of comparison, PBYI is a better buy in the long-term than VNDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBYI’s TA Score shows that 5 TA indicator(s) are bullish while VNDA’s TA Score has 2 bullish TA indicator(s).

  • PBYI’s TA Score: 5 bullish, 3 bearish.
  • VNDA’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, PBYI is a better buy in the short-term than VNDA.

Price Growth

PBYI (@Biotechnology) experienced а -10.27% price change this week, while VNDA (@Biotechnology) price change was -5.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

PBYI is expected to report earnings on Feb 27, 2025.

VNDA is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VNDA($254M) has a higher market cap than PBYI($146M). VNDA has higher P/E ratio than PBYI: VNDA (126.00) vs PBYI (6.32). PBYI YTD gains are higher at: -2.623 vs. VNDA (-8.977). PBYI has higher annual earnings (EBITDA): 49.4M vs. VNDA (-30.16M). VNDA has more cash in the bank: 376M vs. PBYI (96.7M). VNDA has less debt than PBYI: VNDA (7.94M) vs PBYI (86.4M). PBYI has higher revenues than VNDA: PBYI (244M) vs VNDA (191M).
PBYIVNDAPBYI / VNDA
Capitalization146M254M57%
EBITDA49.4M-30.16M-164%
Gain YTD-2.623-8.97729%
P/E Ratio6.32126.005%
Revenue244M191M128%
Total Cash96.7M376M26%
Total Debt86.4M7.94M1,088%
FUNDAMENTALS RATINGS
PBYI vs VNDA: Fundamental Ratings
PBYI
VNDA
OUTLOOK RATING
1..100
7471
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2390
PRICE GROWTH RATING
1..100
6061
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (46) in the Biotechnology industry is somewhat better than the same rating for VNDA (84). This means that PBYI’s stock grew somewhat faster than VNDA’s over the last 12 months.

PBYI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VNDA (100). This means that PBYI’s stock grew similarly to VNDA’s over the last 12 months.

PBYI's SMR Rating (23) in the Biotechnology industry is significantly better than the same rating for VNDA (90). This means that PBYI’s stock grew significantly faster than VNDA’s over the last 12 months.

PBYI's Price Growth Rating (60) in the Biotechnology industry is in the same range as VNDA (61). This means that PBYI’s stock grew similarly to VNDA’s over the last 12 months.

VNDA's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for PBYI (100). This means that VNDA’s stock grew significantly faster than PBYI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBYIVNDA
RSI
ODDS (%)
Bearish Trend 11 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 11 days ago
76%
Momentum
ODDS (%)
Bullish Trend 11 days ago
80%
Bearish Trend 11 days ago
76%
MACD
ODDS (%)
Bullish Trend 11 days ago
83%
Bullish Trend 11 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
83%
Bearish Trend 11 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
83%
Bearish Trend 11 days ago
75%
Advances
ODDS (%)
Bullish Trend 12 days ago
84%
Bullish Trend 16 days ago
68%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
90%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 11 days ago
76%
View a ticker or compare two or three
Ad is loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VNDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GEMNX23.020.17
+0.74%
GMO Emerging Markets R6
MFWIX16.170.05
+0.31%
MFS Global Total Return I
CCASX79.950.19
+0.24%
Conestoga Small Cap Investors
GUBGX15.00N/A
N/A
Victory RS International A
HIAHX16.55-0.11
-0.66%
Hartford Healthcare HLS IA

PBYI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with ABCL. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
-1.66%
ABCL - PBYI
36%
Loosely correlated
+1.02%
ARVN - PBYI
35%
Loosely correlated
+2.67%
MDGL - PBYI
34%
Loosely correlated
+7.64%
VNDA - PBYI
33%
Loosely correlated
-1.80%
AURA - PBYI
31%
Poorly correlated
+1.30%
More

VNDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VNDA has been loosely correlated with AMLX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if VNDA jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VNDA
1D Price
Change %
VNDA100%
-1.80%
AMLX - VNDA
42%
Loosely correlated
+2.86%
GOSS - VNDA
37%
Loosely correlated
-3.81%
IKNA - VNDA
37%
Loosely correlated
-0.66%
VCYT - VNDA
36%
Loosely correlated
-1.27%
ATRA - VNDA
34%
Loosely correlated
-16.09%
More